Novo Nordisk Signs US$252.6 M Deal with EraCal to Boost Obesity Portfolio

By Amit Kaushik

Pharma Deals Review: Vol 2024 Issue 2 (Table of Contents)

Published: 8 Feb-2024

DOI: 10.3833/pdr.v2024.i2.2852     ISSN: 1756-7874

Section: Research & Development



In a groundbreaking move with the potential to revolutionise the treatment of obesity, Novo Nordisk has entered into a licensing agreement with EraCal Therapeutics to develop and commercialise a small molecule investigational obesity therapeutic to control appetite and body weight...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details